Pay in 4 interest-free payments of $6.16 Learn more
Ships within 48 hours · Estimated delivery Aug 29 - Sep 3
It should not be used in patients with acidosis and should be used with extreme caution in patients with severe liver disease
Summary: Current evidence does not establish a definitive causal relationship between weight loss injections (GLP-1 receptor agonists) and pancreatitis, though UK regulatory guidance lists pancreatitis as a potential adverse effect requiring monitoring
Protocols, doses, and reactions reported below come from clinical trials and community sources
Retatrutide is the only compound in advanced clinical investigation that simultaneously activates the GLP-1, GIP, and glucagon receptors
US$ 28.44
US$ 20.49
US$ 26.44
US$ 20.55
US$ 24.32
US$ 21.15
